Details of the Drug

General Information of Drug (ID: DMYHSO2)

Drug Name
ABT-874
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 3 [1]
Rheumatoid arthritis FA20 Phase 1 [1]
Crohn disease DD70 Discontinued in Phase 2 [1]
Cross-matching ID
TTD ID
D0H1TL
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-12 beta (IL12B) TTGW72V IL12B_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Rheumatoid arthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-12 beta (IL12B) DTT IL12B 9.01E-01 1.32E-02 0.07
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
2 Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20.